IP Library Granted Patent US 7,033,793
Granted Patent B2
US 7,033,793 · App. 10/171,384 · Granted Apr 25, 2006

P53 binding protein-related protein in cardiomyopathy

Assignee: The Brigham and Women's Hospital, Inc.
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,033,793
App. No.
10/171,384
Granted
Apr 25, 2006
Kind
B2
Abstract

The present invention is directed to a mouse model of dilated cardiomyopathy in which animals are deficient in the expression of a gene encoding a p53 binding protein-related protein (PRP). The invention also encompasses the mouse PRP gene and protein themselves as well as counterparts found in the human. The various genes and proteins can be used in making transgenic animals and in assays designed to determine the likelihood of an individual developing cardiomyopathy.

Claims (8)

1. A substantially pure polynucleotide, wherein said polynucleotide consists of a sequence encoding the PRP protein, wherein said protein comprises the amino acid sequence of SEQ ID NO:1.

2. A vector for recombinantly expressing mouse PRP, comprising a coding region consisting of the polynucleotide of claim 1 operably linked to a promoter.

3. An isolated host cell transformed with the vector of claim 2 .

4. The polynucleotide of claim 1 , wherein said polynucleotide comprises the sequence of SEQ ID NO: 2.

5. A DNA construct suitable for homologous recombination, comprising a targeting segment consisting of the nucleotide sequence of SEQ ID NO:2, wherein:

(a) a portion of the nucleotide sequence of said targeting segment has been interrupted or replaced with a marker nucleotide sequence;

(b) said targeting segment is capable of integrating into the genome of a mouse host cell at the site of the endogenous PRP gene when said construct is introduced into said mouse host cell; and

(c) a mutant allele is produced which is incapable of synthesizing a fully functional PRP gene product when said targeting segment is integrated at the site of said endogenous PRP gene.

Assignments (3)
CONFIRMATORY LICENSE Recorded Apr 12, 2017
From: PARTNERS HEALTHCARE INNOVATION
To: NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR
Reel/Frame 041983/0327 →
CONFIRMATORY LICENSE Recorded Jun 2, 2009
From: BRIGHAM AND WOMEN'S HOSPITAL
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 022763/0821 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 23, 2002
From: BEIER, DAVID R.; HERRON, BRUCE; RAO, CHERIE
To: BRIGHAM AND WOMEN'S HOSPITAL, INC., THE
Reel/Frame 013487/0536 →
Continuity (2)
Provisional Application 6029916000 · Jun 20, 2001
Related Publication 20030031680A1 · Feb 13, 2003